Manufacturers report positive results for apabetalone for reduction in cardiovascular events in chronic kidney disease

In the BETonMACE study, this BET inhibitor selective for the second bromodomain (BD2) within the BET proteins reduced major cardiovascular adverse events (including cardiovascular disease related death and heart failure) by 52% vs placebo.

Biospace Inc.